|
gptkbp:instance_of
|
gptkb:fund
|
|
gptkbp:assets
|
$1.5 billion
|
|
gptkbp:created_by
|
gptkb:State_Street_Global_Advisors
|
|
gptkbp:distribution
|
Quarterly
|
|
gptkbp:dividend_yield
|
Available
1.50%
|
|
gptkbp:financial_performance
|
4 stars
|
|
gptkbp:focus_area
|
gptkb:United_States
|
|
gptkbp:frequency
|
Quarterly
|
|
gptkbp:funding
|
Large
0.35%
Open-end fund
Sector fund
|
|
gptkbp:has_a_focus_on
|
Pharmaceutical sector
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SPDR S& P Pharmaceuticals ETF Trust
|
|
gptkbp:inception
|
2006-01-26
|
|
gptkbp:investment
|
gptkb:Annual
Growth
Long-term capital appreciation
Market risk
$1,000
|
|
gptkbp:investment_focus
|
Pharmaceutical companies
|
|
gptkbp:investment_strategy
|
Sector investing
|
|
gptkbp:launch_date
|
2006-01-26
|
|
gptkbp:management
|
gptkb:State_Street_Global_Advisors
|
|
gptkbp:market
|
gptkb:High
|
|
gptkbp:market_capitalization_focus
|
Large-cap
|
|
gptkbp:mentor
|
gptkb:State_Street_Global_Advisors
|
|
gptkbp:notable_products
|
Equities
|
|
gptkbp:number_of_holdings
|
gptkb:30
|
|
gptkbp:performance
|
gptkb:S&_P_Pharmaceuticals_Select_Industry_Index
gptkb:S&_P_500_Index
Positive
Above average
|
|
gptkbp:portfolio_company
|
gptkb:Low
|
|
gptkbp:regulatory_body
|
gptkb:Securities_and_Exchange_Commission
|
|
gptkbp:revenue
|
gptkb:None
0.25%
|
|
gptkbp:risk_management
|
Moderate
|
|
gptkbp:shares
|
Common shares
|
|
gptkbp:stock_symbol
|
XPH
|
|
gptkbp:track
|
gptkb:S&_P_Pharmaceuticals_Select_Industry_Index
gptkb:Low
|
|
gptkbp:traded_on
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:type_of
|
gptkb:High
|
|
gptkbp:values
|
$50
|
|
gptkbp:bfsParent
|
gptkb:SPDR_ETFs
|
|
gptkbp:bfsLayer
|
6
|